aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

Rhea-AI Summary

aTyr Pharma, Inc. (LIFE) to report Q4 and full year 2023 financial results on March 14, 2024. Conference call and webcast scheduled to discuss the results and provide a corporate update.

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Date: Thursday, March 14, 2024
Time: 5:00 p.m. EDT / 2:00 p.m. PDT
Dial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b725cac9cc6
Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts

Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at investorrelations@atyrpharma.com.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

FAQ

When will aTyr Pharma report its Q4 and full year 2023 financial results?

aTyr Pharma will report its fourth quarter and full year 2023 financial results on Thursday, March 14, 2024.

What is the ticker symbol for aTyr Pharma?

The ticker symbol for aTyr Pharma is LIFE.

When is the conference call and webcast scheduled to discuss the financial results?

The conference call and webcast to review the financial results and provide an operational update will be held on Thursday, March 14, 2024, at 5:00 p.m. EDT / 2:00 p.m. PDT.

How can participants join the conference call by telephone?

Participants who wish to join the conference call by telephone must register at the provided dial-in registration link to receive the dial-in number and a personalized PIN code required to access the call.

Where can participants access the live webcast?

Participants can join the live webcast by accessing it at the provided webcast registration link on the aTyr Events page.